transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Diagnosis and biomarkers: CSF

Författare och institution:
B. Mollenhauer (-); Henrik Zetterberg (Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi)
Publicerad i:
Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management, s. 97-108
Kapitel, refereegranskat
Cambridge University Press
Sammanfattning (abstract):
n the last two decades, the elucidation of the molecular pathology of several neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD), has resulted in new biomarkers that have increased our knowledge on distinct and shared pathologies, as well as temporal dynamics in the appearance of pathology, in neurodegenerative diseases. This knowledge has resulted in new thoughts on neuropreventive strategies and how to monitor the pharmacodynamic effects of such treatments. Commencing with the finding of extracellular secretion of β-amyloid (Aβ) in 1992, followed by numerous validation studies, the analysis of Aβ fragments 1-42 (Aβ1-42) in cerebrospinal fluid (CSF) in combination with total and/or phosphorylated tau protein was recently (together with neuroimaging methods) included in research criteria for the clinical diagnosis of the most frequent dementia disorder, AD [1]. Along similar lines, the Alzheimer’s Association and the National Institute on Aging of the National Institutes of Health have worked on new diagnostic criteria and guidelines for AD, which were published in April 2011 [2]. These guidelines postulate three clinically relevant stages of the disease, with a continuum between and within each stage. The first stage is a preclinical phase, which might last a decade or more. In this phase there is evidence of abnormal biomarker patterns, such as low CSF Aβ1-42 levels and/or increased amyloid tracer retention on positron emission tomography (PET) of the brain, but without signs of cognitive impairment [3]. The second stage is designated mild cognitive impairment due to AD [4].
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Medicinska grundvetenskaper ->
Neurovetenskaper ->
Postens nummer:
Posten skapad:
2015-03-17 15:46
Posten ändrad:
2015-03-17 15:47

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007